Impact of Genetic Testing on the Outcome of Kidney Transplant Recipient Evaluation

Background: Identifying a genetic etiology during evaluation of kidney transplant (KT) candidates can inform the risk of disease recurrence, guide KT management, and enable the assessment of living related donors. Despite these benefits, there is limited literature on the impact of genetic testing on recipient candidate outcomes. Methods: Eighty patients who underwent KT evaluation in January 2021 to November 2022 were assessed. Patients with positive genetic test results were compared with patients without any identified kidney disease related genetic variants. The primary outcomes were waitlisting, KT and delayed graft function (DGF). Results: Positive genetic test results were found in 44 (55%) patients, with APOL1 high risk genotypes (20, 45%), PKD1/2 (6, 14%) and COL4A3-4 variants (4, 9%) being the most common. There were no significant differences between patients with positive and negative test results in terms of age, sex, self-identified race and cause of kidney disease. The criteria for testing are shown in Figure 1. During a median follow up of 2 yrs (IQR,1.75-2.58), 63% of the patients were waitlisted and 45% underwent KT. Waitlisting, deceased (DDKT) and living donor KT (LDKT) rates did not differ significantly between patients with positive and negative genetic results (Waitlisting: 28 (64%) vs 22 (61%),p=0.82; DDKT: 16 (36%) vs 14 (39%) and LDKT: 2 (5%) vs 3 (8%),p=0.58). DGF rates were similar between patients with positive and negative results (3 (7%) vs 3 (8%),p=0.59). Four patients with positive genetic test results developed biopsy confirmed rejection while no rejection episodes were recorded in patients with negative genetic results (p=0.039). Conclusion: In this pilot study, genetic testing with positive findings in KT evaluations did not significantly impact waitlisting, transplant and DGF risk of recipient candidates. Higher rate of rejection in patients with positive genetic test results needs further studies.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.2024t5n4f5n7
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of Genetic Testing on the Outcome of Kidney Transplant Recipient Evaluation

Barış Afşar, Krista L. Lentine, Dzuy Truong, Henry B. Randall et al.
Journal of the American Society of Nephrology
Renal Transplantation Outcomes and Treatments
article

Impact of Genetic Testing on the Outcome of Kidney Transplant Recipient Evaluation

Barış Afşar, Krista L. Lentine, Dzuy Truong, Henry B. Randall, Rengin Elsürer Afşar, Fadee Abu Al Rub, Mustafa Nazzal, Bahar Bastani, Vidya A. Fleetwood, Chintalapati Varma, Yasar Caliskan, Ava DeLonais-Dick, Kate Rabideau
article en

Abstract

Background: Identifying a genetic etiology during evaluation of kidney transplant (KT) candidates can inform the risk of disease recurrence, guide KT management, and enable the assessment of living related donors. Despite these benefits, there is limited literature on the impact of genetic testing on recipient candidate outcomes. Methods: Eighty patients who underwent KT evaluation in January 2021 to November 2022 were assessed. Patients with positive genetic test results were compared with patients without any identified kidney disease related genetic variants. The primary outcomes were waitlisting, KT and delayed graft function (DGF). Results: Positive genetic test results were found in 44 (55%) patients, with APOL1 high risk genotypes (20, 45%), PKD1/2 (6, 14%) and COL4A3-4 variants (4, 9%) being the most common. There were no significant differences between patients with positive and negative test results in terms of age, sex, self-identified race and cause of kidney disease. The criteria for testing are shown in Figure 1. During a median follow up of 2 yrs (IQR,1.75-2.58), 63% of the patients were waitlisted and 45% underwent KT. Waitlisting, deceased (DDKT) and living donor KT (LDKT) rates did not differ significantly between patients with positive and negative genetic results (Waitlisting: 28 (64%) vs 22 (61%),p=0.82; DDKT: 16 (36%) vs 14 (39%) and LDKT: 2 (5%) vs 3 (8%),p=0.58). DGF rates were similar between patients with positive and negative results (3 (7%) vs 3 (8%),p=0.59). Four patients with positive genetic test results developed biopsy confirmed rejection while no rejection episodes were recorded in patients with negative genetic results (p=0.039). Conclusion: In this pilot study, genetic testing with positive findings in KT evaluations did not significantly impact waitlisting, transplant and DGF risk of recipient candidates. Higher rate of rejection in patients with positive genetic test results needs further studies.

Journal of the American Society of NephrologyVol. 35(10S)
Saint Louis University (US)
Openalex Percentile: Top 64%
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.